Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Integrity Implant System Post Market Clinical Follow-Up Study

NCT06741527 · tracked via the Priya Life Science USA tracker
Sponsor
Anika Therapeutics, Inc
Phase
Not applicable
Started
2025-02-01
Last updated
2026-06-24

Condition(s) studied

Rotator Cuff Tears of the Shoulder

Investigational drug(s) / intervention(s)

Integrity Implant System

Integrity Implant System: Integrity Implant System used for Rotator Cuff Repair

Study summary

The study design is a prospective, multi-center, single-arm, non-randomized post market clinical follow-up study to confirm the performance, safety and clinical benefit of the Integrity Implant System when used for rotator cuff tear augmentation (with or without repair).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
1. At least 18 years of age 2. Able (with assistance from LAR, if necessary) to understand the informed consent process, including regulatory requirements such as HIPAA authorization, and document informed consent prior to completion of any study-related procedures. 3. Able to complete all Patient Reported Outcome Measure (PROM) questionnaires. 4. Fully understands study requirements and able to return for all required follow-up visits and assessments. 5. Able to comply with all post-operative physician prescribed rehabilitation instructions. 6. Index shoulder rotator cuff tendon tear surgical access may be performed using mini-open, single-portal arthroscopic or multi-portal arthroscopic intervention 7. Meets all intended use and indications for use defined within the Integrity Implant System IFUs as applied to rotator cuff tendon tears. These include: Index shoulder rotator cuff tendon tear needs management and protection from injury Index shoulder has no substantial loss of tendon tissue Index shoulder rotator cuff tendon tear footprint allows approximation of soft tissue and fixation of the Integrity Implant to tendon tissue using an Integrity Tissue Tack Index shoulder rotator cuff tendon tear footprint allows fixation of the Integrity Implant to bone using the Integrity Bone Staple Exclusion Criteria The subject exclusion criteria are as follows: 1. Medical condition that in the PI's opinion would place the subject at risk or interfere with the study 2. Vulnerable population (prisoners, minors, pregnant women, mentally ill persons and the elderly or any person under any undue pressure from others to participate in the study) 3. Pregnant, breastfeeding, or plans to become pregnant during the study 4. History of poor compliance with medical treatment of any kind 5. Deemed contraindicated for MRI by the PI 6. Previous rotator cuff surgery (any type) on the index shoulder 7. Current instability of the index shoulder 8. Rotator cuff tendon tear is a Massive Cofield Classified Full-Thickness Tear (tear length \>5cm) 9. Chondromalacia of index shoulder ≥ Grade 3 10. Fatty infiltration of the index shoulder rotator cuff muscle ≥ Grade 3 11. Insulin dependent Type I Diabetes 12. History of heavy smoking (≥ 1 pack per day) within last 6-months 13. History of auto-immune or immunodeficiency disorders 14. Currently taking immunosuppression medication for other diseases (e.g., transplants or other inflammatory diseases) 15. Oral steroid use in the last 2-months or injectable steroid use in the last 3-months 16. History of cognitive or mental health status that interferes with study participation 17. Poor comprehension of English language 18. Meets one or more of the contraindications defined within the Integrity Implant System IFUs as applied to rotator cuff tendon tears. These include: 18.1 Rotator cuff tendon tear is deemed irreparable by the PI 18.2 Rotator cuff tendon tear repair requires replacement of damaged tendon 18.3 Rotator cuff tendon tear repair requires fixation of soft tissue to adjoining soft tissue 18.4 Rotator cuff tendon tear repair requires tendon strength reinforcement 18.5 Presence of infection 18.6 Any condition which would limit the ability or willingness to restrict activities or follow directions during the healing period 18.7 Hypersensitivity to any of the Integrity Implant System components 18.8 Inadequate soft tissue support for Integrity Tissue Tack fixation 18.9 Inadequate quality of bone for Integrity Bone Staple fixation

Primary outcome measure(s)

  • Re-tear rate after rotator cuff augmentation — 12 months postoperatively
    Assessed by MRI evaluation at 12 months post-operatively defined using Sugaya classification system.

Trial sites (9)

FacilityCityRegionStatus
OrthoArizona Gilbert Arizona Recruiting
Premier Orthopaedic Trauma Specialists, PMC Pomona California Recruiting
Foundation for Orthopaedic Research and Education Tampa Florida Recruiting
Harbin Clinic Rome Georgia Recruiting
Central Indiana Orthopaedics Fishers Indiana Recruiting
Towson Orthopaedic Associates/University of Maryland St. Joseph's Medical Center Towson Maryland Recruiting
Virtua Health Marlton New Jersey Recruiting
Steadman Hawkins Clinic of the Carolinas Greenville South Carolina Recruiting
Campbell Clinic Germantown Tennessee Recruiting

More Anika Therapeutics, Inc. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06741527 on ClinicalTrials.gov ↗ ← All trials in the USA